Literature DB >> 22576078

Human Herpesvirus-6 cytopathic inclusions: an exceptional and recognizable finding on skin biopsy during HHV6 reactivation after autologous stem-cell transplantation.

Jennifer Roux1, Maxime Battistella, Luc Fornecker, Jérôme Legoff, Bénédicte Deau, Nadira Houhou, Jean-David Bouaziz, Catherine Thieblemont, Anne Janin.   

Abstract

Skin rash are common in immunocompromised patients, particularly after bone marrow transplantation. Human herpes virus 6 (HHV6) reactivation is often suspected, but its clinical presentation and the routine laboratory tests may be unspecific, thus leading to late diagnosis. In this case, we report specific intralymphocytic cytopathic inclusions on skin biopsy as a sign of systemic HHV6 reactivation. A 56-year-old patient presented progressive erythroderma and fever occurring after autologous hematopoietic stem-cell transplantation for mantle cell lymphoma. The skin biopsy showed a perivascular infiltrate of medium-to-large lymphocytes with irregular nuclei containing a large central basophilic inclusion surrounded by a clear halo. High levels of HHV-6 genomic in skin biopsy confirm HHV-6-induced cytopathic effect. The clinical course improved with intravenous foscavir. The specific histopathological findings encountered in this case are exceptional but recognizable, and along with HHV-6 DNA detection allow a prompt recognition of HHV6 skin rash.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576078     DOI: 10.1097/DAD.0b013e31825667ed

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  2 in total

1.  Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT.

Authors:  Joshua A Hill; W Garrett Nichols; Francisco M Marty; Genovefa A Papanicolaou; Thomas M Brundage; Randall Lanier; Danielle M Zerr; Michael J Boeckh
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

Review 2.  Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials.

Authors:  Joshua A Hill; Danielle M Zerr
Journal:  Curr Opin Virol       Date:  2014-10-04       Impact factor: 7.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.